| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-11 and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-11 and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.
1 This work was supported in part by a Grant-in-Aid for Scientific Research provided by the Ministry of Education, Science, Sports and Culture of Japan and in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan.
2 To whom requests for reprints should be addressed.
Received 11/13/96. Accepted 3/25/97.
This article has been cited by other articles:
|
|
 |
|
  M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS Drug Metab. Dispos., March 1, 2005; 33(3): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu and M. A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Onc., December 1, 2002; 13(12): 1841 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guo, W. Marinaro, P. Hu, and P. J. Sinko Delineating the Contribution of Secretory Transporters in the Efflux of Etoposide Using Madin-Darby Canine Kidney (MDCK) Cells Overexpressing P-Glycoprotein (Pgp), Multidrug Resistance-Associated Protein (MRP1), and Canalicular Multispecific Organic Anion Transporter (cMOAT) Drug Metab. Dispos., April 1, 2002; 30(4): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gamcsik, M. S. Kasibhatla, D. J. Adams, J. L. Flowers, O. M. Colvin, G. Manikumar, M. Wani, M. E. Wall, G. Kohlhagen, and Y. Pommier Dual Role of Glutathione in Modulating Camptothecin Activity: Depletion Potentiates Activity, but Conjugation Enhances the Stability of the Topoisomerase I-DNA Cleavage Complex Mol. Cancer Ther., November 1, 2001; 1(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) Clin. Cancer Res., August 1, 2001; 7(8): 2182 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.M. SCHELLENS, M. MALIEPAARD, R. J. SCHEPER, G. L. SCHEFFER, J. W. JONKER, J. W. SMIT, J. H. BEIJNEN, and A. H. SCHINKEL Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ratain Insights into the Pharmacokinetics and Pharmacodynamics of Irinotecan Clin. Cancer Res., September 1, 2000; 6(9): 3393 - 3394. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Slatter, L. J. Schaaf, J. P. Sams, K. L. Feenstra, M. G. Johnson, P. A. Bombardt, K. S. Cathcart, M. T. Verburg, L. K. Pearson, L. D. Compton, et al. Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients Drug Metab. Dispos., April 1, 2000; 28(4): 423 - 433. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z.-S. Chen, T. Kawabe, M. Ono, S. Aoki, T. Sumizawa, T. Furukawa, T. Uchiumi, M. Wada, M. Kuwano, and S.-I. Akiyama Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion Transporter Mol. Pharmacol., December 1, 1999; 56(6): 1219 - 1228. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Maliepaard, M. A. van Gastelen, L. A. de Jong, D. Pluim, R. C. A. M. van Waardenburg, M. C. Ruevekamp-Helmers, B. G. J. Floot, and J. H. M. Schellens Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line Cancer Res., September 1, 1999; 59(18): 4559 - 4563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Minami, T. E. Lad, M. K. Nicholas, E. E. Vokes, and M. J. Ratain Pharmacokinetics and Pharmacodynamics of 9-Aminocamptothecin Infused Over 72 Hours in Phase II Studies Clin. Cancer Res., June 1, 1999; 5(6): 1325 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Friedman, W. P. Petros, A. H. Friedman, L. J. Schaaf, T. Kerby, J. Lawyer, M. Parry, P. J. Houghton, S. Lovell, K. Rasheed, et al. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., May 1, 1999; 17(5): 1516 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Niinuma, Y. Kato, H. Suzuki, C. A. Tyson, V. Weizer, J. E. Dabbs, R. Froehlich, C. E. Green, and Y. Sugiyama Primary active transport of organic anions on bile canalicular membrane in humans Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1153 - G1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Chu, Y. Kato, and Y. Sugiyama Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats Drug Metab. Dispos., April 1, 1999; 27(4): 440 - 441. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Akhteruzzaman, Y. Kato, A. Hisaka, and Y. Sugiyama Primary Active Transport of Peptidic Endothelin Antagonists by Rat Hepatic Canalicular Membrane J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 575 - 581. [Abstract] [Full Text]
|
|
|
|
|
|
X.-Y. Chu, H. Suzuki, K. Ueda, Y. Kato, S.-I. Akiyama, and Y. Sugiyama Active Efflux of CPT-11 and Its Metabolites in Human KB-Derived Cell Lines J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 735 - 741. [Abstract] [Full Text]
|
|
|
|
|
|
M. Homma, H. Suzuki, H. Kusuhara, M. Naito, T. Tsuruo, and Y. Sugiyama High-Affinity Efflux Transport System for Glutathione Conjugates on the Luminal Membrane of a Mouse Brain Capillary Endothelial Cell Line (MBEC4) J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 198 - 203. [Abstract] [Full Text]
|
|
|
|
|
|
M. Kool, M. v. d. Linden, M. de Haas, F. Baas, and P. Borst Expression of Human MRP6, a Homologue of the Multidrug Resistance Protein Gene MRP1, in Tissues and Cancer Cells Cancer Res., January 1, 1999; 59(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hirohashi, H. Suzuki, K. Ito, K. Ogawa, K. Kume, T. Shimizu, and Y. Sugiyama Hepatic Expression of Multidrug Resistance-Associated Protein-Like Proteins Maintained in Eisai Hyperbilirubinemic Rats Mol. Pharmacol., June 1, 1998; 53(6): 1068 - 1075. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sasabe, Y. Kato, A. Tsuji, and Y. Sugiyama Stereoselective Hepatobiliary Transport of the Quinolone Antibiotic Grepafloxacin and Its Glucuronide in the Rat J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 661 - 668. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
